- Home
- BDX
as 09-18-2025 3:31pm EST
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (27% of 2024 revenue) and BD Interventional (24%) account for the remainder. International revenue accounts for 43% of the company's business.
| Founded: | 1897 | Country: | United States |
| Employees: | N/A | City: | FRANKLIN LAKES |
| Market Cap: | 49.0B | IPO Year: | 1962 |
| Target Price: | $222.75 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 5.47 | EPS Growth: | 12.91 |
| 52 Week Low/High: | $163.33 - $251.99 | Next Earning Date: | 11-06-2025 |
| Revenue: | $21,386,000,000 | Revenue Growth: | 7.86% |
| Revenue Growth (this year): | 9.4% | Revenue Growth (next year): | 4.76% |
Stock Insider Trading Activity of Becton Dickinson and Company (BDX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Fraser Claire | BDX | Director | Sep 10 '25 | Sell | $187.50 | 917 | $171,937.50 | 22,226 | |
| Feld Michael | BDX | EVP & President, Life Sciences | Aug 22 '25 | Sell | $197.99 | 57 | $11,285.43 | 8,360 | |
| HAYES GREGORY | BDX | N/A | Aug 11 '25 | Buy | $191.57 | 5,250 | $1,005,742.50 | 6,046 |
Latest Becton Dickinson and Company News
BDX Breaking Stock News: Dive into BDX Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Should Value Investors Buy Becton, Dickinson and Company (BDX) Stock?
PR Newswire
a day ago
BD Marks 1,000th BD Rhapsody System, Driving Scientific Breakthroughs via Single-Cell Multiomics
Business Wire
2 days ago
Celltrion Pharm Signs Strategic Trilateral Agreement with Becton Dickinson and BD Korea to Accelerate Global PFS CMO Business
Zacks
2 days ago
SOLV Strong Q2 Results Signal Momentum: Is the Stock Worth Buying Now?
MT Newswires
3 days ago
Argus Raises Becton, Dickinson and Company's Price Target to $230 From $220
Argus Research
3 days ago
Analyst Report: Becton, Dickinson And Co.
Argus Research
3 days ago
Market Update: BDX
Zacks
3 days ago
BDX vs. MMSI: Which Stock Should Value Investors Buy Now?
Compare BDX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BDX Becton Dickinson and Company - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.